Abstract
Rare and low frequency variants are not well covered inmost germline genotyping arrays and are understudied in relation to epithelial ovarian cancer (EOC) risk. To address this gap, we used genotyping arrays targeting rarer protein-coding variation in 8,165 EOC cases and 11,619 controls from the international Ovarian Cancer Association Consortium(OCAC). Pooled association analyses were conducted at the variant and gene level for 98,543 variants directly genotyped through two exome genotyping projects. Only common variants that represent or are in strong linkage disequilibrium(LD) with previously-identified signals at established loci reached traditional thresholds for exome-wide significance (P < 5.0×10-7). One of themost significant signals (Pall histologies=1.01×10-13;Pserous=3.54×10-14) occurred at 3q25.31 for rs62273959, amissense variantmapping to the LEKR1 gene that is in LD (r2=0.90) with a previously identified 'best hit' (rs7651446)mapping to an intron of TIPARP. Suggestive associations (5.0×10-5 > P≥5.0 ×10-7) were detected for rare and low-frequency variants at 16 novel loci. Four raremissense variants were identified (ACTBL2 rs73757391 (5q11.2), BTD rs200337373 (3p25.1), KRT13 rs150321809 (17q21.2) and MC2R rs104894658 (18p11.21)), but only MC2R rs104894668 had a large effect size (OR=9.66). Genesmost strongly associated with EOC risk included ACTBL2 (PAML=3.23×10-5; PSKAT-o=9.23×10-4) and KRT13 (PAML=1.67×10-4; PSKAT-o=1.07×10-5), reaffirming variant-level analysis. In summary, this large study identified several rare and low-frequency variants and genes thatmay contribute to EOC susceptibility, albeit with possible small effects. Future studies that integrate epidemiology, sequencing, and functional assays are needed to further unravel the unexplained heritability and biology of this disease.
Original language | English (US) |
---|---|
Pages (from-to) | 3600-3612 |
Number of pages | 13 |
Journal | Human molecular genetics |
Volume | 25 |
Issue number | 16 |
DOIs | |
State | Published - Aug 15 2016 |
ASJC Scopus subject areas
- Molecular Biology
- Genetics
- Genetics(clinical)
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Human molecular genetics, Vol. 25, No. 16, 15.08.2016, p. 3600-3612.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk
AU - behalf of the Ovarian Cancer Association Consortium
AU - AOCS study group
AU - Australian Cancer Study (Ovarian Cancer)
AU - Permuth, Jennifer B.
AU - Pirie, Ailith
AU - Chen, Y. Ann
AU - Lin, Hui Yi
AU - Reid, Brett M.
AU - Chen, Zhihua
AU - Monteiro, Alvaro
AU - Dennis, Joe
AU - Mendoza-Fandino, Gustavo
AU - Anton-Culver, Hoda
AU - Bandera, Elisa V.
AU - Bisogna, Maria
AU - Brinton, Louise
AU - Brooks-Wilson, Angela
AU - Carney, Michael E.
AU - Chenevix-Trench, Georgia
AU - Cook, Linda S.
AU - Cramer, Daniel W.
AU - Cunningham, Julie M.
AU - Cybulski, Cezary
AU - D'Aloisio, Aimee A.
AU - Doherty, Jennifer Anne
AU - Earp, Madalene
AU - Edwards, Robert P.
AU - Fridley, Brooke L.
AU - Gayther, Simon A.
AU - Gentry-Maharaj, Aleksandra
AU - Goodman, Marc T.
AU - Gronwald, Jacek
AU - Hogdall, Estrid
AU - Iversen, Edwin S.
AU - Jakubowska, Anna
AU - Jensen, Allan
AU - Karlan, Beth Y.
AU - Kelemen, Linda E.
AU - Kjaer, Suzanne K.
AU - Kraft, Peter
AU - Le, Nhu D.
AU - Levine, Douglas A.
AU - Lissowska, Jolanta
AU - Lubinski, Jan
AU - Matsuo, Keitaro
AU - Menon, Usha
AU - Modugno, Rosemary
AU - Moysich, Kirsten B.
AU - Nakanishi, Toru
AU - Ness, Roberta B.
AU - Olson, Sara
AU - Winham, Stacey
AU - Goode, Ellen L.
N1 - Funding Information: The authors thank the individuals who participated in this research and all the researchers, clinicians, and staff who made possible the many studies contributing to this work. Funding for this study was supported by the National Institute of Health and the Genetic Associations and Mechanisms in Oncology (GAME-ON), a NCI Cancer Post-GWAS Initiative (U19-CA148112). In addition, we acknowledge the following: AUS: U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729), National Health & Medical Research Council of Australia, Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania, Cancer Foundation of Western Australia; National Health and Medical Research Council of Australia (199600 and 400281). The Australian Ovarian Cancer Study Management Group (D. Bowtell, G. Chenevix-Trench, A. deFazio, D. Gertig, A. Green, P. Webb) and ACS Investigators (A. Green, P. Parsons, N. Hayward, P. Webb, D. Whiteman) thank all the clinical and scientific collaborators (see http://www.aocstudy. org/) and the women for their contribution. GCT & PW are supported by Fellowships from NHMRC; AP is funded by a Medical Research Council studentship; DOV: U.S. National Institutes of Health R01-CA112523 and R01-CA87538; HAW: U.S. National Institutes of Health (R01-CA58598, N01-CN-55424 and N01-PC-67001); HOP: DOD DAMD17-02-1-0669 and NCI K07-CA080668, R01-CA95023, P50-CA159981; NIH/National Center for Research Resources/General Clinical Research Center grant M01-RR000056; R01-CA126841; JPN: Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare; LAX: American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the L & S Milken Foundation; MAL: Funding for this study was provided by research grant R01-CA61107 from the National Cancer Institute, Bethesda, MD; research grant 94 222 52 from the Danish Cancer Society, Copenhagen, Denmark; and the Mermaid I project.; MAC and MAY: National Institutes of Health (R01-CA122443, P30-CA15083, P50-CA136393), Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; MAS: Malaysian Ministry of Higher Education (UM.C/HIR/MOHE/06) and Cancer Research Initiatives Foundation; NCO: National Institutes of Health (R01-CA76016) and the Department of Defense (DAMD17-02-1-0666); NEC: National Institutes of Health R01-CA54419 and P50-CA105009 and Department of Defense W81XWH-10-1-02802; NHS: National Institute of Health (P01-CA87696 and R01-CA49449); ORE: OHSU Foundation; POC: Pomeranian Medical University; NJO: National Cancer Institute (NIH-K07 CA095666, R01-CA83918, NIH-K22-CA138563, and P30-CA072720), the Cancer Institute of New Jersey, and NCI CCSG award (P30-CA008748). POL: Intramural Research Program of the NCI; RMH: Cancer Research UK (no grant number is available); OVA: (MOP-86727, MSH-87734; SEA: Cancer Research UK (C490/A10119 C490/A10124); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge, SEARCH team, Craig Luccarini, Caroline Baynes, Don Conroy; SIS: National Institute of Environmental Health Sciences, (Z01ES044005); SWH: National Institute for Health (R37-CA070867); UKO: The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. We particularly thank I. Jacobs, M. Widschwendter, E. Wozniak, A. Ryan, J. Ford and N. Balogun for their contribution to the study; UCI: NIH R01-CA058860, NIH R01-CA092044, US Public Health Service PSA-042205, and the Lon V Smith Foundation grant LVS-39420; USC: P01-CA17054, P30-CA14089, R01-CA61132, N01-PC67010, R03-CA113148, R03-CA115195, N01-CN025403, and California Cancer Research Program (00-01389V-20170, 2II0200). This study was also supported in part by the Biostatistics and Cancer Informatics Core Facilities at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center (P30-CA076292). Funding Information: Funding for this study was supported by the National Institute of Health and the Genetic Associations and Mechanisms in Oncology (GAME-ON), a NCI Cancer Post-GWAS Initiative (U19-CA148112). In addition, we acknowledge the following: AUS: U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729), National Health & Medical Research Council of Australia, Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania, Cancer Foundation of Western Australia; National Health and Medical Research Council of Australia (199600 and 400281). The Australian Ovarian Cancer Study Management Group (D. Bowtell, G. Chenevix-Trench, A. deFazio, D. Gertig, A. Green, P. Webb) and ACS Investigators (A. Green, P. Parsons, N. Hayward, P. Webb, D. Whiteman) thank all the clinical and scientific collaborators (see http://www.aocstudy. org/) and the women for their contribution. GCT & PW are supported by Fellowships from NHMRC; AP is funded by a Medical Research Council studentship; DOV: U.S. National Institutes of Health R01-CA112523 and R01-CA87538; HAW: U.S. National Institutes of Health (R01-CA58598, N01-CN-55424 and N01-PC-67001); HOP: DOD DAMD17-02-1-0669 and NCI K07-CA080668, R01-CA95023, P50-CA159981; NIH/National Center for Research Resources/General Clinical Research Center grant M01-RR000056; R01-CA126841; JPN: Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare; LAX: American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the L & S Milken Foundation; MAL: Funding for this study was provided by research grant R01-CA61107 from the National Cancer Institute, Bethesda, MD; research grant 94 222 52 from the Danish Cancer Society, Copenhagen, Denmark; and the Mermaid I project.; MAC and MAY: National Institutes of Health (R01-CA122443, P30-CA15083, P50-CA136393), Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; MAS: Malaysian Ministry of Higher Education (UM.C/HIR/MOHE/06) and Cancer Research Initiatives Foundation; NCO: National Institutes of Health (R01-CA76016) and the Department of Defense (DAMD17-02-1-0666); NEC: National Institutes of Health R01-CA54419 and P50-CA105009 and Department of Defense W81XWH-10-1-02802; NHS: National Institute of Health (P01-CA87696 and R01-CA49449); ORE: OHSU Foundation; POC: Pomeranian Medical University; NJO: National Cancer Institute (NIH-K07 CA095666, R01-CA83918, NIH-K22-CA138563, and P30-CA072720), the Cancer Institute of New Jersey, and NCI CCSG award (P30-CA008748). POL: Intramural Research Program of the NCI; RMH: Cancer Research UK (no grant number is available); OVA: (MOP-86727, MSH-87734; SEA: Cancer Research UK (C490/A10119 C490/A10124); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge, SEARCH team, Craig Luccarini, Caroline Baynes, Don Conroy; SIS: National Institute of Environmental Health Sciences, (Z01ES044005); SWH: National Institute for Health (R37-CA070867); UKO: The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. We particularly thank I. Jacobs, M. Widschwendter, E. Wozniak, A. Ryan, J. Ford and N. Balogun for their contribution to the study; UCI: NIH R01-CA058860, NIH R01-CA092044, US Public Health Service PSA-042205, and the Lon V Smith Foundation grant LVS-39420; USC: P01-CA17054, P30-CA14089, R01-CA61132, N01-PC67010, R03-CA113148, R03-CA115195, N01-CN025403, and California Cancer Research Program (00-01389V-20170, 2II0200). This study was also supported in part by the Biostatistics and Cancer Informatics Core Facilities at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center (P30-CA076292). Publisher Copyright: © The Author 2016. Published by Oxford University Press. All rights reserved.
PY - 2016/8/15
Y1 - 2016/8/15
N2 - Rare and low frequency variants are not well covered inmost germline genotyping arrays and are understudied in relation to epithelial ovarian cancer (EOC) risk. To address this gap, we used genotyping arrays targeting rarer protein-coding variation in 8,165 EOC cases and 11,619 controls from the international Ovarian Cancer Association Consortium(OCAC). Pooled association analyses were conducted at the variant and gene level for 98,543 variants directly genotyped through two exome genotyping projects. Only common variants that represent or are in strong linkage disequilibrium(LD) with previously-identified signals at established loci reached traditional thresholds for exome-wide significance (P < 5.0×10-7). One of themost significant signals (Pall histologies=1.01×10-13;Pserous=3.54×10-14) occurred at 3q25.31 for rs62273959, amissense variantmapping to the LEKR1 gene that is in LD (r2=0.90) with a previously identified 'best hit' (rs7651446)mapping to an intron of TIPARP. Suggestive associations (5.0×10-5 > P≥5.0 ×10-7) were detected for rare and low-frequency variants at 16 novel loci. Four raremissense variants were identified (ACTBL2 rs73757391 (5q11.2), BTD rs200337373 (3p25.1), KRT13 rs150321809 (17q21.2) and MC2R rs104894658 (18p11.21)), but only MC2R rs104894668 had a large effect size (OR=9.66). Genesmost strongly associated with EOC risk included ACTBL2 (PAML=3.23×10-5; PSKAT-o=9.23×10-4) and KRT13 (PAML=1.67×10-4; PSKAT-o=1.07×10-5), reaffirming variant-level analysis. In summary, this large study identified several rare and low-frequency variants and genes thatmay contribute to EOC susceptibility, albeit with possible small effects. Future studies that integrate epidemiology, sequencing, and functional assays are needed to further unravel the unexplained heritability and biology of this disease.
AB - Rare and low frequency variants are not well covered inmost germline genotyping arrays and are understudied in relation to epithelial ovarian cancer (EOC) risk. To address this gap, we used genotyping arrays targeting rarer protein-coding variation in 8,165 EOC cases and 11,619 controls from the international Ovarian Cancer Association Consortium(OCAC). Pooled association analyses were conducted at the variant and gene level for 98,543 variants directly genotyped through two exome genotyping projects. Only common variants that represent or are in strong linkage disequilibrium(LD) with previously-identified signals at established loci reached traditional thresholds for exome-wide significance (P < 5.0×10-7). One of themost significant signals (Pall histologies=1.01×10-13;Pserous=3.54×10-14) occurred at 3q25.31 for rs62273959, amissense variantmapping to the LEKR1 gene that is in LD (r2=0.90) with a previously identified 'best hit' (rs7651446)mapping to an intron of TIPARP. Suggestive associations (5.0×10-5 > P≥5.0 ×10-7) were detected for rare and low-frequency variants at 16 novel loci. Four raremissense variants were identified (ACTBL2 rs73757391 (5q11.2), BTD rs200337373 (3p25.1), KRT13 rs150321809 (17q21.2) and MC2R rs104894658 (18p11.21)), but only MC2R rs104894668 had a large effect size (OR=9.66). Genesmost strongly associated with EOC risk included ACTBL2 (PAML=3.23×10-5; PSKAT-o=9.23×10-4) and KRT13 (PAML=1.67×10-4; PSKAT-o=1.07×10-5), reaffirming variant-level analysis. In summary, this large study identified several rare and low-frequency variants and genes thatmay contribute to EOC susceptibility, albeit with possible small effects. Future studies that integrate epidemiology, sequencing, and functional assays are needed to further unravel the unexplained heritability and biology of this disease.
UR - http://www.scopus.com/inward/record.url?scp=85014320352&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014320352&partnerID=8YFLogxK
U2 - 10.1093/hmg/ddw196
DO - 10.1093/hmg/ddw196
M3 - Article
C2 - 27378695
AN - SCOPUS:85014320352
SN - 0964-6906
VL - 25
SP - 3600
EP - 3612
JO - Human Molecular Genetics
JF - Human Molecular Genetics
IS - 16
ER -